Shares of Scholar Rock Holding Corporation (SRRK) gained over 15% on Wednesday morning after the late-stage biopharmaceutical company announced positive results from the Phase 2 trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss.
SRRK is currently trading at $35.95, up $4.80 or 15.38%, on the Nasdaq. The stock opened its trading at $33.50 after closing Tuesday at $31.15. The stock has traded between $6.76 and $46.98 in the past 52-week period.
The trial demonstrated that 30% of total weight loss with tirzepatide alone was due to lean mass loss. Apitegromab therapy (10 mg/kg) with tirzepatide preserved an additional 4.2 pounds (1.9 kilograms) or 54.9% of lean mass compared to tirzepatide alone, leading to higher quality weight loss. Apitegromab with tirzepatide was generally well tolerated by participants.
"GLP therapies have been an effective and important innovation for individuals living with obesity and cardiometabolic disorders; however, these treatments can result in substantial loss of lean muscle mass for patients, leading to unwanted health risks," said Akshay Vaishnaw, President of R&D, Scholar Rock. "We are pleased that the EMBRAZE trial accomplished its objective by achieving its primary endpoint. The results validated our hypothesis that our platform of highly selective myostatin inhibitors has the potential to support healthier weight loss for millions of patients on GLP therapies by safely preserving lean mass."
For comments and feedback: editorial@rttnews.com